970 results match your criteria Lupus Erythematosus Subacute Cutaneous

Cutaneous Manifestations of "Lupus": Systemic Lupus Erythematosus and Beyond.

Int J Rheumatol 2021 18;2021:6610509. Epub 2021 May 18.

Department of Medicine, Division of Rheumatology, Dell Medical School at the University of Texas, Austin 78701, USA.

Lupus, Latin for "wolf," is a term used to describe many dermatologic conditions, some of which are related to underlying systemic lupus erythematosus, while others are distinct disease processes. Cutaneous lupus erythematosus includes a wide array of visible skin manifestations and can progress to systemic lupus erythematosus in some cases. Cutaneous lupus can be subdivided into three main categories: acute cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, and chronic cutaneous lupus erythematosus. Read More

View Article and Full-Text PDF

Predicting Risk of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: CSTAR Cohort Study.

Arthritis Rheumatol 2021 Jun 9. Epub 2021 Jun 9.

Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China.

Objectives: Pulmonary arterial hypertension is a life-threatening complication of systemic lupus erythematosus. However, there is no algorithm to identify those at high risk. We aimed to develop a prediction model for pulmonary arterial hypertension in lupus patients that provides individualized risk estimates. Read More

View Article and Full-Text PDF

Atypical and Rare Forms of Cutaneous Lupus Erythematosus: The Importance of the Diagnosis for the Best Management of Patients.

Dermatology 2021 Jun 3:1-10. Epub 2021 Jun 3.

Section of Dermatology, Department of Health Sciences, University of Genoa, Genoa, Italy.

Lupus erythematosus (LE) is an autoimmune disease with a wide range of clinical and cutaneous manifestations. Along with the well-known typical cutaneous manifestations of LE, some cutaneous manifestations are rarer, but still characteristic, enabling the dermatologist and the general practitioner who know them to suspect cutaneous LE (CLE) and investigate a possible underlying systemic involvement. Indeed, not infrequently a skin manifestation is the first presentation of systemic LE (SLE), and >75% of SLE patients show signs of skin disease during the course of the illness. Read More

View Article and Full-Text PDF

Recognition and Management of Cutaneous Connective Tissue Diseases.

Med Clin North Am 2021 Jul;105(4):757-782

Autoimmune Skin Disease Program, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115, USA. Electronic address:

Connective tissue diseases (CTDs) encompass a broad spectrum of clinical presentations that involve multidisciplinary management. Cutaneous findings are common in CTD and careful examination of these features aids in appropriate diagnosis and subsequent evaluation. Thorough work-up of CTD is crucial to properly identify disease subtypes and systemic involvement. Read More

View Article and Full-Text PDF

Clinical features of tumor necrosis factor-α-inhibitor induced chilblain lupus: A case series.

JAAD Case Rep 2021 Jun 24;12:81-84. Epub 2021 Apr 24.

Department of Dermatology, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.

View Article and Full-Text PDF

Expression pattern of tissue-resident memory T cells in cutaneous lupus erythematosus.

Lupus 2021 May 20:9612033211017218. Epub 2021 May 20.

Department of Dermatology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.

Background: Tissue resident memory T cells (TRMs) persist long-term in peripheral tissues without recirculation, triggering an immediate protective inflammatory state upon the re-recognition of the antigen. Despite evidence incriminating the dysregulation of TRMs in autoimmune diseases, few studies have examined their expression in cutaneous lupus erythematosus (CLE).

Objectives: We aimed to examine whether there are differences among TRM populations in CLE depending on different clinical conditions, such as the CLE subtype or association with systemic lupus erythematosus, and to determine the effect of type I interferon (IFN) on the development of TRMs in CLE. Read More

View Article and Full-Text PDF

Drug-induced subacute cutaneous lupus erythematosus in previously diagnosed systemic lupus erythematosus patients: A case series.

JAAD Case Rep 2021 Jun 9;12:18-21. Epub 2021 Apr 9.

Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

View Article and Full-Text PDF

Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review.

Drug Saf 2021 May 6. Epub 2021 May 6.

Department of Dermatology, San Gallicano Dermatological Institute-IRCCS, Via Elio Chianesi 53, 00144, Rome, Italy.

Three cyclin-dependent kinases 4/6, including palbociclib, ribociclib, and abemaciclib, have been approved for the treatment of patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer. The objective of this study was to evaluate the occurrence and clinical spectrum of cutaneous adverse events in patients with breast cancer following therapy with cyclin-dependent kinase 4/6 inhibitors. A systematic literature search was performed in the PubMed, Cochrane, and EMBASE databases up to November 2020 to evaluate studies published from 2015 to 2020. Read More

View Article and Full-Text PDF

Leprosy as a Diagnostic Challenge in the United States.

Skinmed 2021 1;19(2):137-141. Epub 2021 Apr 1.

Department of Dermatology, Mayo Clinic, Jacksonville, FL.

A 63-year-old woman from Central Florida presented to an outside clinic with a 2-year history of a progressive, asymptomatic cutaneous eruption and arthralgias. Her past medical history was significant for reported seronegative rheumatoid arthritis, for which adalimumab, methotrexate, and low-dose prednisone therapy were initiated 5 years prior. The skin eruption occurred shortly after a 4-week hospitalization during which these medications were withheld. Read More

View Article and Full-Text PDF

Role of biomarkers in the diagnosis and prognosis of patients with cutaneous lupus erythematosus.

Ann Transl Med 2021 Mar;9(5):429

Department of Dermatology, University of Texas at Southwestern Medical Center, Dallas, TX, USA.

Cutaneous lupus erythematosus (CLE) is a connective tissue disease with varying presentations, and clinical sequelae including itching, dyspigmentation, and scarring. CLE can occur as its own entity or in conjunction with systemic disease, known as systemic lupus erythematosus (SLE). Because CLE is clinically diverse, identification of a biomarker may help not only facilitate early diagnosis and management but also identify individuals at risk for poor prognosis and development of SLE. Read More

View Article and Full-Text PDF

Neuropsychiatric manifestations in an adolescent male with Rowell syndrome.

J Postgrad Med 2021 Apr-Jun;67(2):109-112

Department of Pathology, Yenepoya Medical College, Yenepoya (Deemed to be University), Mangalore, Karnataka, India.

A 15-year-old boy presented with fever, skin, and oral lesions for 4 weeks. The cutaneous lesions were suggestive of subacute cutaneous lupus erythematosus and erythema multiforme. His clinical, histopathological, and immunological features were indicative of Rowell syndrome and he satisfied the diagnostic criteria of Rowell syndrome proposed by Zeitouni et al. Read More

View Article and Full-Text PDF

Recent Insight on the Management of Lupus Erythematosus Alopecia.

Clin Cosmet Investig Dermatol 2021 30;14:333-347. Epub 2021 Mar 30.

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.

Lupus erythematosus (LE) is a chronic autoimmune condition with a wide spectrum of clinical presentations. Alopecias, both non-scarring and scarring, frequently occur in the context of LE and can assume several different patterns. Furthermore, alopecia occurring with LE may be considered LE-specific if LE-specific features are present on histology; otherwise, alopecia is considered non-LE-specific. Read More

View Article and Full-Text PDF

The Koebner phenomenon on tattoos and piercings in a patient with cutaneous lupus: a case report and review of the literature.

Acta Dermatovenerol Alp Pannonica Adriat 2021 Mar;30(1):43-46

Department of Dermatology, West Réunion Hospital Center, Saint Paul, France.

The Koebner phenomenon is associated with cutaneous lupus erythematosus (CLE). A 20-year-old woman with a 10-year history of systemic lupus, treated with hydroxychloroquine and methotrexate, presented with features of chronic discoid lupus erythematosus (DLE) on the scalp, at the site of ear piercings, and on the temporal bone at the site of trauma from her jewelry. She also had subacute CLE (SCLE) lesions on old black tattoos. Read More

View Article and Full-Text PDF

Dermoscopic Appearance of an Annular Subacute Cutaneous Lupus Erythematosus.

Dermatol Pract Concept 2021 Mar 8;11(2):e2021013. Epub 2021 Mar 8.

Department of Pathology, AIIMS, Bhubaneswar, India.

View Article and Full-Text PDF

NKG2D and its ligands as cytotoxic factors in cutaneous lupus erythematosus.

Exp Dermatol 2021 Jun 9;30(6):847-852. Epub 2021 Mar 9.

Department of Dermatology and Allergy, University of Bonn, Bonn, Germany.

Cutaneous lupus erythematosus (CLE) is an autoimmune skin disorder that is characterized by an anti-epidermal lymphocytic infiltrate invading the dermo-epidermal junction, causing an interface dermatitis (ID). Pathogenesis of CLE has been linked to activation of innate immunity. NKG2D is an innate immune receptor on NK cells and distinct T-cell populations. Read More

View Article and Full-Text PDF

Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience.

Breast Cancer Res Treat 2021 Mar 8. Epub 2021 Mar 8.

Dermatology Department, Skin Unit, The Royal Marsden NHS Foundation Trust, Fulham Road, London, SW3 6JJ, UK.

Purpose: Treatment with Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, has demonstrated significantly improved progression-free survival in patients with hormone receptor-positive, HER2-negative, advanced breast cancer, when used in combination with letrozole or fulvestrant endocrine therapies. However, limited information exists on its cutaneous adverse effects (AE). Hence, we conducted a retrospective cohort study to investigate the prevalence and management of cutaneous AE during palbociclib and endocrine therapy. Read More

View Article and Full-Text PDF

Subacute cutaneous lupus erythematosus triggered after measles vaccination.

Lupus 2021 Apr 11;30(5):833-835. Epub 2021 Feb 11.

Dermatology clinic, Faculdade Meridional 130248IMED, Passo Fundo-RS, Brazil.

Subacute cutaneous lupus erythematosus (SCLE) is a subtype of cutaneous lupus erythematosus that can be triggered by endogenous or exogenous factors. Among the exogenous factors are some medications, drugs, tobacco, infections, and vaccines. In this context, the benefits of vaccination are questioned because although it is important to prevent infections in immunosuppressed patients a theoretical risk of developing systemic lupus erythematosus (SLE) remains in these patients. Read More

View Article and Full-Text PDF

Cutaneous, systemic features and laboratory characteristics of late- versus adult-onset systemic lupus erythematosus in 1006 Thai patients.

Lupus 2021 Apr 7;30(5):785-794. Epub 2021 Feb 7.

Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Background: Age at disease onset may modulate systemic lupus erythematosus (SLE), but its relation to cutaneous/extracutaneous manifestation remains understudied.

Objective: To compare the cutaneous, systemic features, laboratory characteristics, and disease severity between late- and adult-onset SLE patients.

Methods: Analyses of the cutaneous, systemic involvement, laboratory investigations, SLE disease activity index 2000 (SLEDAI-2K), and disease damage were performed to compare between groups. Read More

View Article and Full-Text PDF

Brodalumab-induced subacute cutaneous lupus erythematosus.

Clin Exp Dermatol 2021 Jul 9;46(5):926-927. Epub 2021 Mar 9.

Department of Dermatology, University Hospital of Wales, Cardiff, UK.

View Article and Full-Text PDF

Tofacitinib-induced subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis.

Mod Rheumatol Case Rep 2021 Feb 18:1-4. Epub 2021 Feb 18.

Department of Rheumatology, Ankara Yıldırım Beyazıt University Medical Faculty, Ankara, Turkey.

Tofacitinib is a Janus kinase inhibitor that is employed in the treatment of several diseases, especially rheumatoid arthritis (RA), to prevent joint damage and reduce disease activity. Drug-induced lupus erythematosus (DILE) is a disorder that is linked to some drugs and is characterised by regression of clinical signs and symptoms after discontinuation of the drug. A 56-year-old woman who was diagnosed with RA for 20 years was admitted to the rheumatology department. Read More

View Article and Full-Text PDF
February 2021

Late onset of subacute cutaneous lupus erythematosus following pembrolizumab therapy.

Eur J Cancer 2021 Mar 21;145:168-170. Epub 2021 Jan 21.

Department of Allergy and Dermatology, Gentofte and Herlev Hospital, Denmark; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

View Article and Full-Text PDF

Subacute cutaneous lupus erythematosus induced by PD-1 Inhibitor therapy: two case reports and literature review.

Australas J Dermatol 2021 May 23;62(2):e347-e349. Epub 2021 Jan 23.

Department of Dermatology, Hospital Universitario Miguel Servet, Zaragoza, Spain.

View Article and Full-Text PDF

Lupus erythematosus: Significance of dermatologic findings.

Ann Dermatol Venereol 2021 Mar 19;148(1):6-15. Epub 2021 Jan 19.

Faculty of medicine, University of Strasbourg, and Dermatology clinic, Strasbourg university hospital, Strasbourg, France. Electronic address:

Herein, the different skin manifestations in patients with lupus erythematosus are reviewed, and their diagnostic, pathogenic and prognostic relevance are discussed, as well as their impact on therapeutic choices. The so-called specific lesions of LE result from an autoimmune pathomechanism and they allow diagnosis of LE by simple clinicopathological correlation since the findings are characteristic. They include the classic acute, subacute and chronic variants, characterised microscopically by interface dermatitis; the dermal variants of lupus, such as tumid lupus, displaying dermal perivascular lymphocytic infiltrate with mucin deposition under the microscope, and lupus profundus, in which lymphocytic lobular panniculitis progressing to hyaline fibrosis is found. Read More

View Article and Full-Text PDF

Subacute cutaneous lupus erythematosus in a patient with Sjögren's syndrome taking terbinafine for onychomycosis.

Acta Reumatol Port 2020 Oct-Dec;45(4):288-292

Instituto Português de Reumatologia.

We report the case of a 40-year old woman followed at our Rheumatology department for a 14-year history of a relatively well controlled Sjögren's syndrome who developed, for the first time in life, lesions suggestive of subacute cutaneous lupus erythematosus, nine weeks after taking oral terbinafine prescribed for onychomycosis. She denied additional symptoms, namely systemics, and no other clinical finding besides cutaneous lesions were detected. No laboratory findings were in favour of a flare of her connective tissue disease. Read More

View Article and Full-Text PDF
January 2021

Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.

Lupus 2021 03 6;30(3):531-533. Epub 2021 Jan 6.

Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.

View Article and Full-Text PDF

Drug-induced subacute cutaneous lupus erythematosus associated with abatacept.

Lupus 2021 Apr 22;30(4):661-663. Epub 2020 Dec 22.

Division of Dermatology, Department of Medicine, University of Louisville, Louisville, USA.

Numerous drugs have been linked to the induction or exacerbation of systemic cutaneous lupus erythematosus (SCLE). This report presents the third case of the biologic abatacept as an exacerbating medication for SCLE. A 73-year old woman with a remote history of subacute cutaneous lupus and rheumatoid arthritis, well controlled on hydroxychloroquine, presented with worsening annular erythematous, slightly scaly plaques on her forearms and hands. Read More

View Article and Full-Text PDF

Dermatologic Manifestations, Histologic Features and Disease Progression among Cutaneous Lupus Erythematosus Subtypes: A Prospective Observational Study in Asians.

Dermatol Ther (Heidelb) 2021 Feb 5;11(1):131-147. Epub 2020 Dec 5.

Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Introduction: Cutaneous manifestations are central to the primary diagnosis of systemic lupus erythematosus (SLE). However, information on the clinical, histopathologic, and direct immunofluorescence (DIF) features among subtypes of cutaneous lupus erythematosus (CLE), as well as longitudinal prospective observational study to evaluate the natural history and the progression to SLE, is lacking among Asians. Our objectives are to summarize the differences in the clinical, histopathologic, and DIF characteristics and serological profiles between various subtypes of CLE, and to provide its natural history and the association with disease activity in our Asian population. Read More

View Article and Full-Text PDF
February 2021

[Paraneoplastic subacute cutaneous lupus erythematosus].

Z Rheumatol 2021 Mar 24;80(2):189-193. Epub 2020 Nov 24.

Klinik für Dermatologie, Venerologie und Allergologie, HELIOS St. Elisabeth Klinik Oberhausen, Universität Witten/Herdecke, Josefstr. 3, 46045, Oberhausen, Deutschland.

Subacute cutaneous lupus erythematosus (SCLE) is a subtype of cutaneous lupus erythematosus characterized by high photosensitivity, the occurrence of annular or papulosquamous skin lesions located in body regions exposed to UV light, the presence of anti-Ro/SS‑A antibodies, and mild systemic involvement, such as arthralgia and myalgia. Similar to other subtypes of cutaneous lupus erythematosus, certain trigger factors exist for the development of SCLE, such as exposure to UV light, cigarette smoking and drugs. Rheumatic diseases, such as dermatomyositis, have been known as paraneoplastic syndromes for a long time. Read More

View Article and Full-Text PDF